Learn about a prescription treatment option that could help.

Learn More
PATIENT SITE
  • SIGNIFICANT CONSEQUENCES
  • UNKNOWN RISKS
  • KNOWN RISKS
  • TARGET BREAKTHROUGH SEIZURES
  • GET RESOURCES
  • Patient Site
  • SIGNIFICANT CONSEQUENCES
  • UNKNOWN RISKS
  • KNOWN RISKS
  • TARGET BREAKTHROUGH SEIZURES
  • GET RESOURCES
  • Patient Site
When your patient responds to treatment, but still has seizures, it's...
How they happen

Seizure freedom is the goal. ...but can we know all the risks and obstacles each patient is facing?



  • Many variables put epilepsy patients at risk for breakthrough seizures—seizures that happen even when treatment has been working for some time.1,2 Those breakthrough seizures, especially convulsive seizures, can come with significant consequences3,4
  • We don’t always know why an epilepsy patient has a breakthrough seizure.2 While some precipitating factors are well understood, how they may apply to the case of a particular patient can be more difficult to gauge.1,2 The good news is, we can collaborate with patients and caregivers to take concrete steps to help mitigate unknown risks and known risks
  • We all want to help our patients achieve and maintain convulsive seizure freedom, and we know that missed anticonvulsant doses is just one of many risk factors.2 How we evaluate, treat, and monitor our patients can make an enormous difference. What else can we do to target breakthrough seizures?

SIGNIFICANT CONSEQUENCES

The consequences of breakthrough seizures can be dire―but there are many ways to help mitigate these risks.

HEALTH

Substantial premature mortality from sudden unexpected death in epilepsy (SUDEP), status epilepticus, seizure-related injuries, and suicide3,4

  • In neurology, SUDEP is second only to stroke as a cause of total years of potential life lost3,4
  • More than 3 convulsive seizures in a year increases risk of SUDEP by a factor of 155
  • In one study, most seizure-related injuries were reported for convulsive seizures―42% secondarily generalized, 35% generalized at onset6
  • There are many ways to help mitigate the risks of SUDEP―arm your patients with that knowledge

For ideas on how to counsel patients on SUDEP, view the SUDEP Discussion Guide.

RELATIONSHIP
AND SOCIAL

Depression, cognitive decline, and decline in social functioning7-10

  • Cognitive decline is strongly correlated with the number of convulsive seizures9
  • Children with epilepsy have shown social competency deficiency, memory impairment, depression, and anxiety8,10,11

FINANCIAL

Job loss (with health insurance coverage interruptions), missed work due to comorbidities, and increased treatment costs7,12


Patients with breakthrough seizures had 8.1x higher epilepsy-related costs.12


  • Cost of ER visits12
  • Loss of ability to work (e.g. driver’s license suspension)7,13


"Patients who do not share a bedroom
and have generalized tonic-clonic seizures
had 67 times the risk of SUDEP."14


Even a brief discussion with patients and their caregivers
about SUDEP may save lives.3

DOWNLOAD THE SUDEP DISCUSSION GUIDE


"Some people are on relatively thin ice when it comes to seizure control.
They’re sensitive to small changes in AED blood levels."15

  • Jacqueline French, MD, Professor of Neurology at New York University's School of Medicine


UNKNOWN RISKS

Each patient has different needs and challenges that put them at varying levels of risk for breakthrough seizures. We should design each patient’s treatment plan to manage both known and unknown risks.

While some risks can be predicted, as when a patient presents with a high seizure frequency3, the degree of risk from other factors is not always known. Such risk factors may include patient sensitivity to:

  • Drops in AED plasma levels16
  • Menstrual hormone changes and instability of anticonvulsant plasma levels17
  • Other unknown factors

We don't always know why a treatment isn't working. Some risks are unknown because we lack visibility into a patient's situation.
A deeper look might reveal challenges such as:

  • Poor adherence because of personal difficulties18
  • Poor adherence because of comorbidities, such as depression19
  • Cognitive difficulties due to medication side effects18,19
  • Deliberate dose skipping due to medication side effects18,20
  • Overmedication or undermedication due to misunderstood instructions21
  • Inability to afford a consistent medication supply20,21
  • Unreported side effects21
  • Unreported breakthrough seizures2
  • Unreported or emergent comorbidities18


"Patients with breakthrough seizures
had 8.1 times higher epilepsy-related
financial costs
."14


Help your patients Manage the risks
and Avoid the costs.

DOWNLOAD PDF

KNOWN RISKS

Could understanding patient realities help us guide them toward better outcomes?

Patients have differing needs and challenges, and each breakthrough seizure is a story we don't know. We can't help unless we know what obstacles are getting in the patient's way. Improved quality of life is possible for many people with epilepsy—with help, including education, acknowledgment, and treatment.20

  • Living with epilepsy is itself a risk: comorbidities, social stigma, economic difficulties, and psychological and social challenges can be part of the mix.3,18 We should acknowledge these challenges in our treatment plans and take steps to counter them
  • Triggers cannot always be avoided. Even when you've prescribed an effective medication, a breakthrough seizure could be triggered by irregular or insufficient sleep, alcohol consumption, and stress22
  • A single missed dose can lead to a breakthrough seizure7,23
  • Nearly 50% of people with epilepsy surveyed reported having a breakthrough seizure following a missed dose23,*

In one study,
88% of nonadherent epilepsy patients felt uncomfortable telling their doctor about
a missed dose
.7


  • Patient nonadherence can be a serious obstacle to seizure freedom. For many conditions, 80% adherence is considered acceptable, but in epilepsy the stakes are high and there is very little give with most medications3,12
  • Is what we're asking of patients—"near-perfect adherence"—even possible?3 It's important to acknowledge how challenging this is, along with what's at stake

*A 10-item, nationwide postal survey of 661 patients conducted between 2001 and 2002.


Use the Breakthrough Seizure Risk Assessment
Tool
as a starting point to discuss your patient's risk
factors for breakthrough seizures.


"I'm facing significant life events
(such as changes to relationships,
moving, a new job)."


HCP RISK ASSESSMENT TOOL
PATIENT RISK ASSESSMENT TOOL


TARGET BREAKTHROUGH SEIZURES

Give patients the tools they need to aim for seizure freedom, so we can move beyond the therapeutic inertia
prevalent in so many chronic conditions.24

Consider a multi-pronged approach to improve risk identification:

Use the Breakthrough Seizure Risk Assessment Tool to assess your patient, evaluate responses,
and based on patient responses, create a comprehensive, realistic plan of action.7,20

  • Establish adherence expectations for your patient
  • Prescribe with an eye to patient barriers and challenges—and the likelihood of the patient
    keeping medications within a therapeutic range
  • Set up a timeline for your patient to put plan components in place
  • Probe for potential obstacles to seizure freedom, such as:
  • A busy and unpredictable schedule
  • A stressful job, deadline pressures, or being in school
  • Poor diet and inconsistent meal times (sudden changes in metabolism such as a drop in blood sugar or
    sodium, and deficiencies in certain nutrients, such as calcium, have all been found to trigger seizures)25,26
  • Irregular or insufficient sleep
  • Drinking alcohol or taking recreational drugs
  • Other physical or mental health issues
  • Encourage your patient to report seizures, and discuss any breakthrough seizures they may be having
  • Move beyond guilt and shame—understand how challenging "near-perfect" adherence can be
  • Work with the patient to create a plan, including:
  • A Seizure Plan for caregivers, so they know how to respond and what to do. The Epilepsy Foundation is a useful resource
  • Regular check-ins, especially when a new medication is prescribed, or a change is made to the treatment plan
  • Adjust the treatment regimen to fit the patient's life. Consider medications:
  • With fewer daily doses or once-daily dosing20
  • With alternative formulations (i.e. chewable tablet, oral suspension, sprinkle capsules)20
  • Engineered for sustained release or with a long half-life, to help achieve and sustain stable,
    steady-state plasma levels that stay within the therapeutic range20,27
  • Suggest that the patient develop reminder strategies to help them increase adherence
    and decrease seizure frequency, such as:7,20
  • Using a pillbox
  • Getting medication reminders via app or email
  • Displaying their medication schedules and checking off each dose

Use the Breakthrough Seizure Risk Assessment
Tool
as a starting point to discuss your patient's risk
factors for breakthrough seizures.


"What is the patient's attitude
toward treatment?"


HCP RISK ASSESSMENT TOOL
PATIENT RISK ASSESSMENT TOOL


"Everyone with epilepsy and everyone who treats people with epilepsy need to know that controlling seizures will save lives."4



RESOURCES

Use these free resources to spark discussions with your patients.

BREAKTHROUGH SEIZURE RISK
ASSESSMENT TOOL

Use this tool with your patients as a quick way to learn
which risk factors for breakthrough seizures are most
prevalent in their lives.

HCP RISK ASSESSMENT TOOL
PATIENT RISK ASSESSMENT TOOL

SUDEP DISCUSSION GUIDE

Even a brief discussion with patients and their
caregivers about SUDEP may save lives.3

View more information on SUDEP. DOWNLOAD

SUDEP=sudden unexpected death in epilepsy


MANAGE THE RISK,
AVOID THE COST

What are the costs of not managing the risk of
breakthrough seizures? Have these talking points
at hand to share with patients.

DOWNLOAD
Learn more about prescription treatment options

Talk with your patients about breakthrough seizures—
especially convulsive seizures.

Some anticonvulsants have a narrow therapeutic range.29 Discuss a treatment
option that may help mitigate some of the risk.

Learn More

References: 1. Hughes DM, Bonnett LJ, Marson AG, García-Fiñana M. Identifying patients who will not reachieve remission after breakthrough seizures. Epilepsia. 2019;60(4):774-782. 2. Bonnett LJ, Powell GA, Tudur Smith C, Marson AG. Breakthrough seizures-Further analysis of the Standard versus New Antiepileptic Drugs (SANAD) study. PLoS One. 2017;12(12):e0190035. 3. Devinsky O, Hesdorffer DC, Thurman DJ, et al. Sudden unexpected death in epilepsy: Epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075-88. 4. Devinsky O, Spruill T, Thurman D, et al. Recognizing and preventing epilepsy-related mortality: A call for action. Neurology. 2016;86(8):779-786. 5. Hesdorffer DC, Tomson T, Benn E, et al. Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia. 2012;53(2):249-252. 6. Friedman DE, Tobias RS, Akman CI, et al. Recurrent seizure-related injuries in people with epilepsy at a tertiary epilepsy center: A 2-year longitudinal study. Epilepsy Behav. 2010;19(3):400-404. 7. Hovinga CA, Asato MR, Manjunath R, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians. Epilepsy Behav. 2008;13(2):316-322. 8. Tellez-Zenteno JF, Patten SB, Jetté N, et al. Psychiatric comorbidity in epilepsy: A population-based analysis. Epilepsia. 2007;48(12):2336-2344. 9. Thompson PJ, Duncan JS. Cognitive decline in severe intractable epilepsy. Epilepsia. 2005;46(11):1780-1787. 10. Raud T, Kaldoja ML, Kolk A. Relationship between social competence and neurocognitive performance in children with epilepsy. Epilepsy Behav. 2015;52:93-101. 11. Reilly C, Atkinson P, Chin RF, et al. Symptoms of anxiety and depression in school-aged children with active epilepsy: A population-based study. Epilepsy Behav. 2015;52:174-179. 12. Divino V, Petrilla AA, Bollu V, et al. Clinical and economic burden of breakthrough seizures. Epilepsy Behav. 2015;51:40-47. 13. Ramey PJ, Koubeissi MZ, Azar NJ. Quality of Life in Epilepsy. In: Koubeissi MZ, Azar NJ, eds. Epilepsy Board Review. New York, NY: Springer; 2017. 14. Nashef L, Rugg-Gunn F. Reducing the risk of SUDEP: From uncertainty to reality. Neurology. 2020;95(18):807-808. 15. French, Jacqueline. “Epilepsy Medications: When Is It Safe to Substitute a Generic?” FACES (Finding a Cure for Epilepsy and Seizures). NYU Langone Health, 2016,

faces.med.nyu.edu/news/epilepsy-medications-when-it-safe-substitute-generic. Accessed October 29, 2020. 16. Marvanova M. Pharmacokinetic characteristics of antiepileptic drugs (AEDs). Ment Health Clin. 2016;6(1):8-20. 17. Schachter S, Devinsky O, Cramer J. Discussion Guide. Epilepsy Therapy Project. https://www.epilepsy.com/sites/core/files/atoms/files/discussion_guide.pdf. Accessed November 2, 2020. 18. Ferrari CM, de Sousa RM, Castro LH. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 2013;22(5):384-389. 19. Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385-407. 20. Eatock J, Baker GA. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr Dis Treat. 2007;3(1):117-131. 21. Epilepsy Foundation. “Noncompliance.” Epilepsy Foundation, 9 May 2008, www.epilepsy.com/learn/professionals/refractory-seizures/potentially-remediable-causes/noncompliance. Accessed October 29, 2020. 22. Epilepsy Society. “Seizure Triggers.” Epilepsy Society, 14 May 2020, www.epilepsysociety.org.uk/living-epilepsy/epileptic-seizures/seizure-triggers. 23. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3(4):338-342. 24. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834. 25. Ettinger AB, Adiga RK. Breakthrough Seizures—Approach to Prevention and Diagnosis. US Neurology, 2008;4(1):40-42. 26. Epilepsy Foundation. “Nutritional Deficiencies as a Seizure Trigger.” Epilepsy Foundation, December 2006, https://www.epilepsy.com/learn/triggers-seizures/nutritional-deficiencies. Accessed November 3, 2020. 27. Wheless JW, Phelps SJ. A clinician's guide to oral extended-release drug delivery systems in epilepsy. J Pediatr Pharmacol Ther. 2018;23(4):227-292. 28. Verducci C, Hussain F, Donner E, et al. SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies. Neurology. 2019;93(3):e227-e236. 29. Greenberg RG, Melloni C, Wu H, et al. Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach. Clin Neuropharmacol. 2016;39(5):232-240.

This website contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other healthcare professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent healthcare decisions, you should always consult with a physician or other healthcare provider for your, or your loved one's, personal medical needs. All quotes included in this website represent the individual experience of some doctors, some patients, and their caregivers. Individual responses to treatment may vary.

This site is intended for residents of the United States only.

Catalyst Pharmaceuticals, Inc.

©2023 Catalyst Pharmaceuticals, Inc. EPI-0004 July 2023

EPILAPSEY® is a registered trademark of Catalyst Pharmaceuticals, Inc.

Privacy Policy